Loading provider…
Loading provider…
Hematology & Oncology Physician in Brighton, CO
NPI: 1013979566Primary Practice Location
INTERMOUNTAIN HEALTH PLATTE VALLEY HOSPITAL
1600 Prairie Center Pkwy, Brighton, CO
Primary Employer
Platte Valley Medical Group LLC
plattevalleymed.com
HQ Phone
Get MD Firas's Phone Numberphone_androidMobile
Get MD Firas's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardFL State Medical License
CO State Medical License
2022 - 2027
FL State Medical License
2005 - 2024
AR State Medical License
1995 - 2005

American Board of Internal Medicine
Medical Oncology
University of Florida
Fellowship • Hematology and Medical Oncology
2003 - 2006
University of Arkansas for Medical Sciences (UAMS) College of Medicine
Residency • Internal Medicine
1994 - 1997
University of Jordan Faculty of Medicine
Medical School
Until 1992
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 115 | 180 |
| 2 | 99213Established patient office or other outpatient visit, typically 15 minutes | 38 | 40 |
| 3 | 99215Established patient office or other outpatient, visit typically 40 minutes | 34 | 50 |
| 4 | 99205New patient office or other outpatient visit, typically 60 minutes | 26 | 26 |
| 5 | 99204New patient office or other outpatient visit, 45-59 minutes | 13 | 13 |
Results of autologous stem cell transplant in multiple myeloma patients with renal failure.
Authors: Yousri Barri, Ashraf Badros, Guido Tricot, Elias Anaissie, Bart Barlogie
Journal: Br J Haematol
Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning.
Authors: Lee, C. K., Badros, A., Barlogie, B., Morris, C., Zangari, M., Fassas, A., van Rhee, F., Cottler-Fox, M., Jacobson, J., Thertulien, R., Muwalla, F., Mazher, S., Anaissie, E., Tricot, G.
Hairy cell leukemia with CCND1/IGH fusion gene and BRAF V600E mutation.
Authors: James Foran, Zaid Abdel Rahman, Liuyan Jiang
Publication Date: 2020-03-17
Lead Sponsor: CTI BioPharma
Intervention / Treatment: DRUG: Gemcitabine + Rituximab, DRUG: Pixantrone + Rituximab
Lead Sponsor: Bristol-Myers Squibb
Collaborators: ICON Clinical Research